METASTATIC ENDOMETRIAL CARCINOMA
Clinical trials for METASTATIC ENDOMETRIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC ENDOMETRIAL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC ENDOMETRIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with endometrial cancer that had returned or spread. The goal was to see if the combination could slow or stop cancer growth. Participants had already tried other treatments and their cancer ha…
Matched conditions: METASTATIC ENDOMETRIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:56 UTC
-
Engineered virus targets Hard-to-Treat endometrial cancer in early trial
Disease control OngoingThis early-phase trial tests a specially designed virus that may selectively attack cancer cells while sparing healthy ones. The study includes up to 34 people with advanced or recurrent endometrial cancer. The main goal is to find the safest dose and understand side effects, wit…
Matched conditions: METASTATIC ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 06:48 UTC
-
New combo attack on Hard-to-Treat cancers shows early promise
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (which blocks a DNA repair enzyme)—in people with advanced solid tumors that have a HER2 mutation. The goal is to find the safest dose and see if the combo wo…
Matched conditions: METASTATIC ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:45 UTC
-
New drug combo shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs, APG-1252 and cobimetinib, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the drugs can shrink or stabilize tumors. About 42 adults with advanced or recurrent cance…
Matched conditions: METASTATIC ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:09 UTC